OncLive® On Air

In today’s episode, we had the pleasure of speaking with Jacob Sands, MD, and Shailee Shah, MD, about considerations for diagnosing and managing Lambert-Eaton myasthenic syndrome (LEMS), particularly in the context of small cell lung cancer (SCLC). Dr Sands is associate chief of the Lowe Center for Thoracic Oncology and the Oncology Medical Director of the International Patient Center at Dana-Farber Cancer Institute, as well as an assistant professor at Harvard Medical School in Boston, Massachusetts. Dr Shah is a clinical assistant professor of neurology (MS/neuroimmunology) at the Northwestern University Feinberg School of Medicine in Chicago, Illinois. In our exclusive interview, Drs Sands and Shah discussed LEMS symptom identification, the importance of paraneoplastic panels for assessing neurologic dysfunction in patients with SCLC, the need for specific autoantibody testing, and what guidelines currently note as best practices for the diagnosis of this disease. 

Welcome to OncLive On Air®!OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.In today’s episode, we had the pleasure of speaking with Joshua Richter, MD, about the rationale and implications for the phase 1 CAMMA 1 study (NCT04910568), which is investigating the bispecific antibody cevostamab (RG6160; BFCR4350A) in patients with relapsed/refractory multiple myeloma. Dr Richter is an associate professor of medicine at The Tisch Cancer Institute and director of Multiple Myeloma at the Blavatnik Family Chelsea Medical Center at Mount Sinai in New York, New York.In our exclusive interview, Dr Richter discussed the rationale for targeting FcRH5 in the development of therapies for multiple myeloma, the evaluation of cevostamab-based combination strategies in patients with relapsed/refractory disease, and what the future may hold in this research arena. 

Welcome to OncLive On Air®!OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.In today’s episode, we had the pleasure of speaking with Cassie Kline, MD, MAS, about updated efficacy data from the phase 2 FIREFLY-1 study (NCT04775485) of tovorafenib (Ojemda) in patients with relapsed/refractory pediatric low-grade glioma (pLGG) that were presented at the 2025 Society of Neuro-Oncology Annual Meeting. Dr Kline is an attending physician and director of Clinical Research in the Department of Neuro-Oncology at Children's Hospital of Philadelphia in Pennsylvania.In our exclusive interview, Dr Kline discussed longer-term efficacy and safety data from the trial, noting the sustained response rates, continued tumor shrinkage, and rates of patients who remained treatment free after approximately 36 months of follow-up._____That’s all we have for today! Thank you for listening to this episode of OncLive On Air. Check back throughout the week for exclusive interviews with leading experts in the oncology field.For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.OncLive is also on social media. On X and BlueSky, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.If you liked today’s episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!Thanks again for listening to OncLive On Air.*OncLive On Air is available on: Apple Podcasts, Spotify, CastBox, Podcast Addict, Podchaser, RadioPublic, and TuneIn.This content is a production of OncLive; this OncLive On Air podcast episode is supported by funding, however, content is produced and independently developed by OncLive.

Daniel Spratt, MD, dives into groundbreaking updates in prostate cancer treatment guidelines. He discusses the shift towards personalized androgen deprivation therapy (ADT) for localized cases and introduces the oral GnRH antagonist, relugolix. The conversation highlights molecularly guided options for metastatic CRPC and the impact of ADT on quality of life, including potential cardiovascular risks and financial toxicity. Spratt also predicts a future where biomarkers might help identify patients who could skip hormone therapy, pushing for innovative combinations in cancer care.

In today’s episode,filmed live at the 43rd Annual CFS Chemotherapy Foundation Symposium, lung cancer expert Benjamin P. Levy, MD, hosted a cross-specialty discussion with breast cancer experts Kamel Abou Hussein, MD, and Victoria Rizk, MD, about the rapidly evolving therapeutic landscape in breast cancer. Dr Levy is the clinical director of medical oncology at the Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital and an associate professor of oncology at the Johns Hopkins University School of Medicine in Washington, DC. Dr Abou Hussein is co-director of the Janet Knowles Breast Cancer, director of Breast Medical Oncology, and director of Breast Cancer Clinical Trials at Cooper University Health Care; as well as an assistant professor of medicine at Cooper Medical School of Rowan University in Camden, New Jersey. Dr Rizk is a medical oncologist at Tampa General Hospital Cancer Institute in Florida.

In today’s episode, we had the pleasure of speaking with Marc S. Raab, MD, about the post-induction outcomes and updated minimal residual disease (MRD) analyses from the phase 2 MajesTEC-5 study (NCT05695508), which is evaluating teclistamab-cqyv (Tecvayli)–based induction regimens in patients with newly diagnosed multiple myeloma. Dr Raab is a professor of medicine at Heidelberg University in Germany.

Welcome to OncLive On Air®!OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.In today’s episode, we had the pleasure of speaking with Harry P. Erba, MD, PhD, about the FDA approval of ziftomenib (Komzifti) for the treatment of adult patients with relapsed/refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation who have no satisfactory alternative treatment options. Dr Erba is a professor of medicine in the Division of Hematologic Malignancies and Cellular Therapy in the Department of Medicine at the Duke University School of Medicine, as well as director of the Leukemia Program and director of Phase I Development in Hematologic Malignancies. He is also a member of the Duke Cancer Institute in Durham, North Carolina.In our exclusive interview, Dr Erba discussed the significance of this approval, key efficacy and safety findings from the pivotal phase 1/2 KOMET-001 trial (NCT04067336), and the role ziftomenib may play throughout the evolution of the AML treatment paradigm._____That’s all we have for today! Thank you for listening to this episode of OncLive On Air. Check back throughout the week for exclusive interviews with leading experts in the oncology field.For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.OncLive is also on social media. On X and BlueSky, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.If you liked today’s episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!Thanks again for listening to OncLive On Air.*OncLive On Air is available on: Apple Podcasts, Spotify, CastBox, Podcast Addict, Podchaser, RadioPublic, and TuneIn.This content is a production of OncLive; this OncLive On Air podcast is supported by funding, however, content is produced and independently developed by OncLive.

In today’s episode, we had the pleasure of speaking with Justin Taylor, MD, an associate professor in the Division of Hematology at the University of Miami Miller School of Medicine, about the growing role of artificial intelligence in cancer information–seeking and what this means for clinicians caring for patients with hematologic malignancies. Dr Taylor’s recent work explores how patients are increasingly turning to AI tools to better understand their diagnoses and treatments, and why oncologists must be aware of the accuracy, limitations, and clinical implications of these technologies.

Closing the Gap: Understanding Gender Disparities in Bladder Cancer Care, hosted by Martha K. Terris, MD, FACS, is a limited series spotlighting unique considerations for bladder cancer diagnosis and treatment among women. Dr Terris is department chair and a professor in the Department of Urology, the Witherington Distinguished Chair in Urology, and co-director of the Cancer Center at the Medical College of Georgia at Augusta University. In the final part of this 3-part series, Dr Terris discussed how the early diagnosis of bladder cancer presents a significant challenge, particularly in female patients, who are frequently diagnosed at a later stage of the disease and subsequently respond less favorably to treatment modalities. A crucial component of early detection is the rigorous evaluation of hematuria, she emphasized. Microhematuria is defined strictly by microscopy. Reliance solely on a dipstick test is insufficient; any positive dipstick result necessitates a microscopic examination, she explained. Furthermore, patients currently receiving anticoagulation therapy do not bypass the standard workup, she noted. If hematuria is identified alongside a urinary tract infection or gynecological issue, the urine should be rechecked once the co-existing problem has cleared, she advised. Risk assessment must consider both common and less-recognized factors, particularly in women, according to Terris. Standard risks include exposure to cyclophosphamide or ifosfamide, Lynch syndrome, chronic indwelling Foley catheters, benzene/aromatic amine exposure, and smoking, she added. However, uro-oncologists must actively assess female patients for occupational exposures not traditionally associated with bladder cancer, she said. Patients presenting with microhematuria should be stratified into low-, intermediate-, or high-risk groups, Terris continued. The gold standard evaluation for high-risk patients is a cystoscopy and CT urogram, she reported. The CT urogram involves cross-sectional imaging of the abdomen and pelvis with and without contrast, incorporating delayed images to optimally visualize the renal pelvis and ureters for potential filling defects, she noted. If patients cannot tolerate contrast, an MR urogram is the primary alternative, she stated. If neither CT nor MR urogram can be performed, the default workup is non-contrast CT combined with cystoscopy and retrograde pyelograms, although this requires general anesthesia, she explained. Given that women are often diagnosed with bladder cancer late and face poor outcomes with advanced disease, maintaining a heightened awareness and low threshold for investigation is critical, Terris concluded.

In today’s episode, filmed live at the 43rd Annual Chemotherapy Foundation Symposium, lung cancer expert Benjamin P. Levy, MD, hosted an in-depth discussion with Jonathan W. Lee, MD, MSc, on the evolving therapeutic landscape for EGFR-mutant and HER2-positive non–small cell lung cancer (NSCLC). Dr Levy is the clinical director of medical oncology at the Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital and an associate professor of oncology at the Johns Hopkins University School of Medicine in Washington, DC. Dr Lee is the chief oncology/hematology fellow at Weill Cornell Medicine in New York, New York.